Research programme: protein therapeutics - Arana Therapeutics/GlaxoSmithKline

Drug Profile

Research programme: protein therapeutics - Arana Therapeutics/GlaxoSmithKline

Latest Information Update: 19 Apr 2011

Price : $50

At a glance

  • Originator EvoGenix; GlaxoSmithKline
  • Developer Arana Therapeutics
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
  • 27 Nov 2008 EvoGenix has successfully completed the second project for GlaxoSmithKline
  • 28 Mar 2007 EvoGenix has successfully completed the first project for GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top